

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/633,697
Filing Date	August 5, 2003
First Named Inventor	UMANA, Pablo
Art Unit	1636
Examiner Name	GUZO, David

Attorney Docket Number 1975.0010005/TJS/T-M

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR55	Boyd, P.N., <i>et al.</i> , "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," <i>Molec. Immunol.</i> 32:1311-1318, Pergamon Press (1995)	
	AS55	Davies, J. <i>et al.</i> , "Expression of GnTIII in a Recombinant Anti-CD20 Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for Fc γ RIII," <i>Biotechnol. Bioeng.</i> 74:288-294, John Wiley & Sons, Inc. (August 2001)	
	AT55	De Bree, R., <i>et al.</i> , "Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract," <i>Nucl. Med. Commun.</i> 15:613-627, Lippincott, Williams & Wilkins (1994)	
	AR56	Dürrbach, A., <i>et al.</i> , "Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma <i>in vitro</i> ," <i>Cancer Gene Ther.</i> 6:564-571, Nature Publishing Group (November-December 1999)	
	AS56	Fukuta, K., <i>et al.</i> , "Control of Bisecting GlcNAc Addition to N-Linked Sugar Chains," <i>J. Biol. Chem.</i> 275:23456-23461, The American Society for Biochemistry and Molecular Biology, Inc. (August 2000)	
	AT56	Kaszubowski, P.A., <i>et al.</i> , "A Cytotoxic Monoclonal Antibody to Colon Adenocarcinoma," <i>Cancer Res.</i> 44:1194-1197, American Association for Cancer Research (1984)	
	AR57	Kilmartin, J.V., <i>et al.</i> , "Rat Monoclonal Antitubulin Antibodies Derived by Using a New Nonsecreting Rat Cell Line," <i>J. Cell Biol.</i> 93:576-582, The Rockefeller University Press (1982)	
	AS57	Luiten, R.M., <i>et al.</i> , "Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc ϵ RI bearing cells," <i>Hum. Antibodies</i> 8:169-180, IOS Press (December 1997)	
	AT57	Lund, J., "Multiple Interactions of IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fc γ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains," <i>J. Immunol.</i> 157:4963-4969, The American Association of Immunologists (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/633,697
				Filing Date	August 5, 2003
				First Named Inventor	UMANA, Pablo
				Art Unit	1636
				Examiner Name	GUZO, David
Sheet	2	of	3	Attorney Docket Number	1975.0010005/TJS/T-M

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AR58	Murakami, H., <i>et al.</i> , "Human-Human Hybridomas Secreting Antibodies Specific to Human Lung Carcinoma," <i>In Vitro Cell. Develop. Biol.</i> 21:593-596, Tissue Culture Association, Inc. (1985)	
	AS58	Raju, T.S., <i>et al.</i> , "Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics," <i>Glycobiol.</i> 10: 477-486, IRL Press at Oxford University Press (May 2000)	
	AT58	Sheng, Y., <i>et al.</i> , "Remodeling of Glycoconjugates on CD44 Enhances Cell Adhesion to Hyaluronate, Tumor Growth and Metastasis in B16 Melanoma Cells Expressing β 1, 4-N-Acetylglucosaminyltransferase III," <i>Int. J. Cancer</i> 73:850-858, Wiley-Liss, Inc. (December 1997)	
	AR59	Shields, R.L., <i>et al.</i> , "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fc γ RIII and Antibody-dependent Cellular Toxicity," <i>J. Biol. Chem.</i> 277:26733-26740, The American Society for Biochemistry and Molecular Biology, Inc. (electronically available May 2002)	
	AS59	Surfus, J.E., <i>et al.</i> , "Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors," <i>J. Immunother.</i> 19:184-191, Raven Press (1996)	
	AT59	Umaña, P., <i>et al.</i> , "Tetracycline-Regulated Overexpression of Glycosyltransferases in Chinese Hamster Ovary Cells," <i>Biotechnol. Bioeng.</i> 65:542-549, John Wiley & Sons, Inc. (December 1999)	
	AR60	Valone, F.H., <i>et al.</i> , "Phase Ia/Ib Trial of Bispecific Antibody MDX-210 in Patients with Advanced Breast or Ovarian Cancer That Overexpresses the Proto-Oncogene HER-2/neu," <i>J. Clin. Oncol.</i> 13:2281-2292, American Society for Clinical Oncology (1995)	
	AS60	Wright, A. and Morrison, S.L., "Effect of glycosylation on antibody function: implications for genetic engineering," <i>Trends Biotechnol.</i> 15:26-32, Elsevier Science Publishers (January 1997)	
	AT60	Copy of Supplementary European Search Report for European Application No. 99 91 8731, mailed December 17, 2004, European Patent Office, The Hague	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

3 of 3

Complete if Known

Application Number	10/633,697
Filing Date	August 5, 2003
First Named Inventor	UMANA, Pablo
Art Unit	1636
Examiner Name	GUZO, David
Attorney Docket Number	1975.0010005/TJS/T-M

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AR61	Copy of Office Action for United States Patent Application No. 10/437,388, Umana <i>et al.</i> , filed May 14, 2003, mailed on October 26, 2006	
	AS61	Copy of Office Action for United States Patent Application No. 10/437,388, Umana <i>et al.</i> , filed May 14, 2003, mailed on July 25, 2007	
	AT61	Copy of Office Action for United States Patent Application No. 10/633,699, Umana <i>et al.</i> , filed August 5, 2003, mailed on April 12, 2005	
	AR62	Copy of Office Action for United States Patent Application No. 10/633,699, Umana <i>et al.</i> , filed August 5, 2003, mailed on March 23, 2006	
	AS62	Copy of Office Action for United States Patent Application No. 10/633,699, Umana <i>et al.</i> , filed August 5, 2003, mailed on October 31, 2003	

736925v1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.